Rozart

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rozart

Quick Facts

Property Description
Active ingredient Rosuvastatin
Form Film-coated tablets
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
Common use Lipid-modifying therapy
Origin Synthetic compound

What is Rozart and What Type of Drug is it?

Rozart is a prescription-only medicine containing the active ingredient Rosuvastatin, which is definitively classified as a statin. This pharmacological designation identifies it as an HMG-CoA reductase inhibitor, reflecting its specific action on a liver enzyme essential for internal fat production. Rozart is a synthetic compound designed for systemic use and is considered a foundational therapy within the family of lipid-modifying agents for chronic conditions. As a single-ingredient product, its action is focused solely on lipid metabolism, a mechanism recognized for its effectiveness in stabilizing high cholesterol levels.

What is Rosuvastatin Made Of and How is it Administered?

The essential therapeutic component in Rozart is Rosuvastatin, typically presented as its calcium salt to ensure pharmaceutical stability and predictable absorption. The medicine is manufactured as film-coated tablets, a solid oral preparation that facilitates the delivery of a precise quantity of the active substance into the body. This specific form necessitates the oral administration route, meaning the medicine must be swallowed, allowing the active ingredient to be absorbed and exert its systemic effects. The finished product is composed of the active ingredient and solid pharmaceutical excipients necessary for the tablet form.

What is the General Purpose of Taking a Statin Like Rozart?

The primary general purpose of Rozart is to manage and correct elevated levels of fats, or lipids, in the bloodstream, a condition broadly termed dyslipidemia or hypercholesterolemia. A typical, neutral use scenario involves long-term management for adult patients who require steady-state regulation of blood lipids. It functions by initiating cholesterol biosynthesis inhibition, a process where it acts in the liver to limit the body’s internal production of cholesterol. This targeted action is intended to achieve a meaningful reduction of low-density lipoprotein cholesterol (LDL-C), ultimately helping to normalize the overall lipid profile.

Regulatory References

  1. Rosuvastatin: MedlinePlus Drug Information

What side effects are possible with Rozart?

Possible Side Effects and Safety Information

The official safety profile for Rozart (Rosuvastatin) is structured around categories of adverse reactions and specific patient constraints, as defined by government regulatory documents.

Adverse Reaction Scope

The most frequently documented adverse reactions, classified as Most Frequent (rate ge 2% in clinical trials), include headache, muscle pain (myalgia), nausea, asthenia (weakness), constipation, and abdominal pain.

The primary focus of regulatory observation lies within the Musculoskeletal and Hepatobiliary system-organ classes. Documented serious adverse reactions are rare but include rhabdomyolysis (severe muscle breakdown) and fatal and non-fatal hepatic failure.

Classification Area Documented Observation
Metabolic Officially noted potential for new-onset diabetes mellitus and monitoring of HbA1c and glucose levels.
Renal Proteinuria and hematuria are documented, which may be observed early in therapy or at higher dose levels.

Regulatory Safety Constraints

Rosuvastatin is subject to specific safety limitations. It is officially restricted from use in individuals with active liver disease and in those with unexplained, persistent elevations of serum transaminases. The regulatory profile also notes increased safety risk for certain groups, particularly geriatric patients (age ge 65 years) and those with renal impairment, concerning the development of muscle-related adverse reactions.

This information reflects how official regulatory documents categorize and communicate the medicine's risk profile, emphasizing monitoring for muscle and liver function.

Overdose and Emergency Response

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Experience with acute Rozart (Rosuvastatin) over-exposure is limited. The expected manifestations are generally documented as being consistent with the medicine's known adverse reactions, and no unique, specific symptom profile is listed in regulatory labeling.
Physiological systems affected The primary system concern documented in official labels is musculoskeletal, with a defined risk to the renal system due to the potential progression of muscle injury (myopathy) to rhabdomyolysis.
Population-specific overdose notes Standard regulatory labeling does not explicitly document differing procedural steps or severity classifications for over-exposure management in specific populations, such as pediatric or geriatric patients.

Emergency Actions

Classification Official Regulatory Statement
Immediate medical help required Immediate medical attention must be sought upon any suspected overdose, and official guidance mandates prompt contact with a certified Poison Control Center.
Antidote status No specific antidote is known for Rosuvastatin over-exposure, as confirmed by authoritative prescribing information.
Management measures Treatment is strictly limited to symptomatic and supportive treatment. Furthermore, hemodialysis is not anticipated to be of clinical benefit due to the drug’s high plasma protein binding.

Official Overdose Statements

Regulatory documents define the risk of over-exposure by emphasizing the limited data and the potential for severe systemic complications, including rhabdomyolysis leading to acute renal failure. This necessitates that patients seek immediate medical attention. Because no specific antidote exists, management is restricted to supportive care in a medical setting, which includes mandatory monitoring of Creatine Kinase (CK) levels and liver function tests (LFTs) to assess muscle and hepatic status.

Therapeutic Uses of Rozart

Rozart: Main Uses and Clinical Support

Rozart is a prescription medication utilized in the management of several cardiovascular conditions. It is indicated for the sustained reduction of elevated blood pressure, a condition known as hypertension. Maintaining a supported blood pressure level may contribute to reducing the risk of associated cardiovascular events.

Furthermore, this therapeutic option is used for the management of heart failure. By working to ease the burden on the heart, it may help to support overall cardiovascular function and may contribute to symptom relief. Rozart may also be part of a comprehensive treatment plan to help minimize the occurrence of strokes and heart attacks in individuals with existing risk factors.

Quick Facts

  • Therapeutic Domain 1: Supports the management of high blood pressure (hypertension).
  • Therapeutic Domain 2: Used in the treatment regimen for heart failure.
  • Supportive Role: May contribute to reducing the risk of heart attack and stroke.

For a detailed overview of the approved indications and clinical considerations, consult the professional prescribing information.

Eligibility and Restrictions for Use

Rozart (Rosuvastatin) eligibility is strictly defined by regulatory guidelines to mitigate risks of muscle and liver injury. The medicine is contraindicated and must not be used in several specific populations. This includes patients with a known hypersensitivity to rosuvastatin, those with active liver disease (defined by persistent, unexplained hepatic transaminase elevations), and individuals with severe renal impairment (creatinine clearance < 30 mL/min).

Use is also strictly prohibited during pregnancy and by nursing mothers. Women of childbearing potential are required to use appropriate contraceptive measures.

Eligibility is restricted for patients with certain comorbidities. Those with pre-existing myopathy or those receiving concomitant Ciclosporin must not use the medicine. The maximum 40 mg dose is contraindicated in patients with moderate renal impairment (CrCl < 60 mL/min) and for pediatric use.

For age-group eligibility, the medicine is approved for adults but is not recommended for children younger than six years. Pediatric use is limited to treating specific inherited cholesterol conditions in children generally starting at ages seven or eight. Older adults (age ge 65) are identified as having a predisposing factor for muscle-related risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rosuvastatin, the active ingredient in Rozart, has officially documented interaction patterns primarily driven by drug transporters, not major CYP450 metabolism. The regulatory classification includes contraindicated combinations and those requiring strict co-administration rules.

Category Interaction Entities and Official Restrictions
Contraindicated Combinations Ciclosporin (Cyclosporine) co-administration is strictly contraindicated due to a significant increase in rosuvastatin exposure. The combination of Rosuvastatin and certain anti-viral agents (e.g., Sofosbuvir/Velpatasvir/Voxilaprevir) is not recommended in official labeling.
Transporter-Mediated Exposure Inhibitors of hepatic uptake transporters, such as OATP1B1 and BCRP, including many anti-viral medications and Gemfibrozil, increase Rosuvastatin plasma concentration (AUC), necessitating dose limitations.
Pharmacodynamic Additive Risk Co-administration with other lipid-modifying agents, such as Fibrates (e.g., Gemfibrozil) and lipid-modifying doses of Niacin, creates an additive risk for adverse skeletal muscle effects. The same additive risk applies to Colchicine.
Timing Separation Rules Rosuvastatin must be administered at least 2 hours before Aluminum and Magnesium Hydroxide Combination Antacids to prevent a reduction in the drug's plasma concentration.

Patients of Asian descent may experience increased Rosuvastatin systemic exposure, which is an officially documented factor related to interaction risk. The official label also notes that co-administration with Coumarin Anticoagulants (e.g., Warfarin) prolongs the International Normalized Ratio (INR), requiring frequent monitoring upon initiation or alteration of Rosuvastatin therapy.

Mechanism of Action

Direct Inhibition of Hepatic Cholesterol Production

The fundamental action of Rosuvastatin begins in the liver, where it acts as a competitive inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the rate-limiting step within the mevalonate pathway, which slows the rate of the primary route for internal cholesterol synthesis. This direct enzyme blockade acts within the cellular metabolic system to reduce the internal supply of active cholesterol.


Enhanced Systemic Fat Clearance via Receptor Upregulation

The resulting drop in intracellular cholesterol concentration triggers a key cellular feedback loop: the hepatocyte increases the synthesis and increased expression of Low-Density Lipoprotein (LDL) receptors on its surface. This mechanism increases the liver's capacity to extract and break down circulating LDL particles from the bloodstream, leading to enhanced systemic clearance of these lipoproteins.


Modulation of Vascular Cell Signaling (Pleiotropic Effects)

Beyond its main role in lipid metabolism, the drug influences downstream processes by inhibiting the production of non-sterol intermediates, or isoprenoids. This effect modulates critical signaling proteins in the vascular endothelium, which influences processes related to local inflammation and oxidative stress within the blood vessel walls.

Dosage and Administration Information

Rozart is formulated as film-coated tablets intended exclusively for oral administration. The tablets should be swallowed whole with water. The general use pattern requires the medicine to be taken once daily, and the intake is not dependent on meals, allowing the medicine to be taken with or without food. The time of day for administration is flexible, meaning it can be taken in the morning or evening.

The standard dosing begins at 5 mg or 10 mg once daily. Based on the individual therapeutic needs, the dose may be adjusted within the official adult range of 5 mg to 40 mg. If an adjustment is necessary, it is typically performed after a minimum period of four weeks to allow for the assessment of lipid response. The maximum recommended daily dose is 40 mg, which is generally reserved for patients who have not achieved their treatment goal on a 20 mg regimen.

Usage may be modified for certain populations. For patients with severe renal impairment (non-dialysis), the starting dose is 5 mg, and the dose should not exceed 10 mg daily. For patients of Asian ancestry, a 5 mg starting dose is typically considered. If a daily dose is missed, the standard protocol is to avoid taking an extra dose; the patient should simply resume treatment with the next scheduled dose. Additionally, aluminum- and magnesium-containing antacids should be administered at least two hours after the Rosuvastatin tablet to prevent reduced absorption.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Rozart (Rosuvastatin)


Evidence for Use in Primary Hypercholesterolemia and Mixed Dyslipidemia

Rozart was evaluated in randomized controlled trials (RCTs) and head-to-head studies to examine patterns in individuals with elevated cholesterol levels. These research efforts primarily monitored changes in key blood biomarkers over short and intermediate time periods. The main outcomes evaluated were Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and Apolipoprotein B (ApoB).

Studies reported patterns of change in LDL-C and other lipid markers, including lower measured values compared to baseline levels recorded at the start of the research. However, the evidence from these specific trials is predominantly based on surrogate endpoints, which are changes in blood markers rather than measurements of hard clinical outcomes like a heart attack or stroke.


Research Examining Cardiovascular Event Patterns

Research explored outcomes related to major cardiovascular events in two main contexts: primary prevention (for adults with risk factors but no prior history of heart events) and secondary prevention (for adults with established vascular disease).

For primary prevention, large-scale, long-term RCTs examined outcomes related to heart attacks, strokes, and cardiovascular death. These trials described patterns where the measured occurrence of these hard events was observed at a different rate in the groups receiving Rosuvastatin versus the placebo group.

For secondary prevention, studies monitored outcomes in individuals with existing vascular disease, research examining recurrent major adverse cardiovascular events (MACE). These findings generally describe patterns where differences in the measured rates of these events were observed over time in groups receiving Rosuvastatin.


Evidence in Specific Populations and Research Gaps

Research was evaluated in certain specialized populations, particularly pediatric patients (children and adolescents) with the genetic condition Familial Hypercholesterolemia (FH). The available studies contribute to understanding that patterns of lower measured LDL-C and TC were reported in children and adolescents. However, the sample sizes were modest in the pediatric trials, resulting in limited information regarding long-term effects.

The follow-up durations were limited in many trials focused only on lipid changes. The overall evidence quality varies across studies, and subgroup findings are uncertain for specific ethnic or comorbidity groups. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. NICE Guideline: Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

Frequently Asked Questions (FAQ)

Common questions about Rozart (FAQ)


Q: How quickly does Rozart start to work after I begin taking it?

Official documents state that a patient’s lipid levels are typically analyzed and dosage is assessed within a 2-to-4-week period after treatment begins. This timeframe allows the healthcare provider to assess the biological response to the medication. The medicine is intended for long-term management, and consistent intake is described as necessary for monitoring its full effect.


Q: Are there any major diet restrictions while taking Rozart?

While the Rozart tablet can be taken with or without food, official patient information often advises that the medicine should be used along with a healthcare provider-recommended low-fat, low-sugar, and low-cholesterol diet. Following this dietary approach is generally described as supporting the overall strategy for regulating lipid levels.


Q: Can Rozart be taken with over-the-counter vitamins or supplements?

Regulatory documents indicate that taking Rozart alongside certain over-the-counter supplements, such as Vitamin D, may require monitoring by a healthcare provider. This is because these combinations can sometimes influence the concentration of either agent in the body. Official information suggests disclosing the use of all supplements to a healthcare provider.


Q: How long do I usually have to take Rozart?

Official labeling describes this medication as intended for long-term management. The benefits of the medication, particularly those related to reducing cardiovascular risk, are observed to continue for as long as the medicine is consistently taken.


Q: Can Rozart affect my mood or mental health?

The active ingredient in Rozart belongs to a class of medicines (statins) where post-marketing surveillance has included reports of certain central nervous system effects. This includes reports of depression and memory loss. These events are observed during post-marketing surveillance and are part of the medicine's safety profile.


Q: Are there any serious interactions Rozart has with common antibiotics?

Official studies examining drug interactions have looked at coadministration with certain antibiotics, specifically Erythromycin and Ketoconazole. These studies determined that this coadministration did not result in clinically significant changes to the concentration of rosuvastatin in the body. It is standard practice to disclose all prescription medications, including antibiotics, to the prescribing provider.


Q: Does Rozart interact with alcohol?

Regulatory documents include a specific safety warning regarding alcohol consumption. Official patient information indicates that excessive consumption of alcohol should be avoided or limited. This caution is included to address the potential for an increased risk of side effects affecting the liver.


Q: Is Rozart a controlled substance?

Rozart is classified as a prescription-only medicine and is not listed as a controlled substance. As an authorized prescription drug, it is dispensed by pharmacies under the order of a licensed healthcare provider.


Q: What is the 'half-life' of Rozart?

According to pharmacokinetic data published in official documentation, the elimination half-life of the active ingredient (rosuvastatin) is approximately 19 hours. The half-life is the time it takes for half of the drug to be eliminated from the bloodstream.


Q: Will Rozart impact my ability to drive or operate machinery?

Official patient information indicates that caution is advised when performing activities that require full attention, such as driving a car or operating machinery. This is because the medication is documented to cause dizziness in some individuals.


Q: Does Rozart have a risk of dependence or withdrawal?

Regulatory documents state that Rosuvastatin is not associated with dependence and does not cause withdrawal symptoms when treatment is stopped. However, official sources note that discontinuing the medication may lead to rising cholesterol levels, which is associated with an increase in cardiovascular risk.


Q: How is Rozart removed from the body?

Pharmacokinetic studies show that the active ingredient, rosuvastatin, and its breakdown products are primarily removed from the body through the feces. Approximately 90% of the drug is eliminated this way. A smaller portion is known to be excreted through the kidneys.


Q: Are there generic versions of Rozart available?

The generic version of the medicine, named rosuvastatin, has been officially available since 2016. Because of this, the generic is often the preferred choice for dispensing by many health plans.


Q: What does the drug label say about taking Rozart with grapefruit?

Official drug interaction studies indicate that taking rosuvastatin with grapefruit or grapefruit juice has been shown to result in little or no clinically significant effect. This observation is documented in the product information.


Q: Is Rozart known to cause issues with sleep?

According to official safety updates for the statin class of medicines, post-marketing reports have included experiences of sleep disturbances. These disturbances include issues such as insomnia and nightmares.


Q: Is Rozart a common drug to be prescribed?

Based on prescription volume data collected by regulatory analysts, Rosuvastatin is a commonly prescribed medication. In the United States, for example, data from 2023 placed the active ingredient among the top 15 most frequently prescribed drugs.


Q: Where can I find the official patient information leaflet for Rozart?

Information about official documents is available from regulatory resources such as the DailyMed database, which is maintained by the National Institutes of Health (NIH). These resources can be searched using the active ingredient name, Rosuvastatin.

How should Rozart be stored and disposed of?

The official storage requirements for Rozart (Rosuvastatin) are designated to maintain the product’s quality and strength.

Storage Conditions

Rozart must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F) [FDA Label]. The medication must be protected from moisture and excessive heat to ensure stability.

  • Packaging: Store the tablets in the original container and keep the container tightly closed [MedlinePlus].
  • Child Safety: The product must be stored out of the reach of children [FDA Label].

Disposal Instructions

Expired or unused Rozart should be discarded using a drug take-back program or mail-back envelope, as this is the preferred method [FDA Guidance]. If these options are unavailable, the medication should be mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed container, and thrown into the household trash [FDA Guidance]. All personal information must be removed from the original packaging prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rozart found in:

A-Z Index: